Advanced search
Publication Cover
Cancer Investigation Volume 22, 2004 - Issue 6
Submit an article Journal homepage
410
Views
112
CrossRef citations to date
0
Altmetric
Original Article

Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial

Ramesh K. Ramanathan University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, # 562, Pittsburgh, Pennsylvania, 15232, USA
, M.D.,
Jimmy J. Hwang University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, # 562, Pittsburgh, Pennsylvania, 15232, USA
, M.D.,
William C. Zamboni Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, 15213, USA
,
Frank A. Sinicrope MD Anderson Cancer Center, GI Medicine and Nutrition, 1515 Holcombe Blvd., Box 0436, Houston, Texas, 77030, USA; Cancer Therapy and Evaluation Program, National Cancer Institute, 6130 Executive Blvd., EPN 7131, Rockville, Maryland, 20852, USA
, M.D.,
Howard Safran Brown University, Bio Med Medicine, Box G-MH, Providence, Rhode Island, 02912, USA
,
Michael K. Wong University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, # 562, Pittsburgh, Pennsylvania, 15232, USA
,
Martin Earle University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, # 562, Pittsburgh, Pennsylvania, 15232, USA
,
Adam Brufsky University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, # 562, Pittsburgh, Pennsylvania, 15232, USA
,
Terry Evans University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, # 562, Pittsburgh, Pennsylvania, 15232, USA
,
Monica Troetschel University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, # 562, Pittsburgh, Pennsylvania, 15232, USA
,
Christine Walko Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, 15213, USA
,
Roger Day University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, # 562, Pittsburgh, Pennsylvania, 15232, USA
,
Helen X. Chen Cancer Therapy and Evaluation Program, National Cancer Institute, 6130 Executive Blvd., EPN 7131, Rockville, Maryland, 20852, USA
&
Sydney Finkelstein Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, USA
 show all
Pages 858-865 | Published online: 23 Nov 2004

Citations (112)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (10)

Cristina Smolenschi, Audrey Perret, François Dall’Armellina, Valerie Boige, David Malka, Antoine Hollebecque & Michel Ducreux. (2021) An appraisal of emerging second line therapies for metastatic colorectal cancer. Expert Review of Gastroenterology & Hepatology 15:2, pages 165-179.
Read now
Anna La Salvia, Victoria Lopez-Gomez & Rocio Garcia-Carbonero. (2019) HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. Expert Opinion on Investigational Drugs 28:1, pages 29-38.
Read now
Imane El Dika & David H. Ilson. (2018) Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. Expert Review of Anticancer Therapy 18:11, pages 1085-1092.
Read now
Diana L. Hanna & Heinz-Josef Lenz. (2016) Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Review of Clinical Pharmacology 9:8, pages 1091-1108.
Read now
Do-Youn Oh & Yung-Jue Bang. (2016) Pertuzumab in gastrointestinal cancer. Expert Opinion on Biological Therapy 16:2, pages 243-253.
Read now
Wafik S. El-Deiry, Namrata Vijayvergia, Joanne Xiu, Angelique Scicchitano, Bora Lim, Nelson S. Yee, Harold A. Harvey, Zoran Gatalica & Sandeep Reddy. (2015) Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biology & Therapy 16:12, pages 1726-1737.
Read now
Monica Dandona Desai, Bikramajit Singh Saroya & Albert Craig Lockhart. (2013) Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers. Expert Opinion on Investigational Drugs 22:3, pages 341-356.
Read now
Steven M. Sorscher. (2011) Marked Response to Single Agent Trastuzumab in a Patient with Metastatic HER-2 Gene Amplified Rectal Cancer. Cancer Investigation 29:7, pages 456-459.
Read now
Muhammad W Saif. (2010) Colorectal cancer in review: the role of the EGFR pathway. Expert Opinion on Investigational Drugs 19:3, pages 357-369.
Read now
Peter Nygren, Halfdan Sørbye, Pia Österlund & Per Pfeiffer. (2005) Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncologica 44:3, pages 203-217.
Read now

Articles from other publishers (102)

Samantha M. Ruff, Zachary J. Brown & Timothy M. Pawlik. (2023) A review of targeted therapy and immune checkpoint inhibitors for metastatic colorectal cancer. Surgical Oncology 51, pages 101993.
Crossref
Haojie Zhou, Minzhi Lv, Wei Li, Yan Wang, Jing Wu, Qing Liu, Qian Li, Tianshu Liu & Yuehong Cui. (2023) Efficacy of pyrotinib with/without trastuzumab in treatment-refractory, HER2-positive metastatic colorectal cancer: result from a prospective observational study. Clinical Colorectal Cancer.
Crossref
Vinh Dao & Gregory Heestand. (2023) Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2. Current Problems in Cancer 47:4, pages 100960.
Crossref
Samantha M. Ruff, Alexander H. Shannon & Timothy M. Pawlik. (2023) The Role of Targeted Therapy in the Multi-Disciplinary Approach to Colorectal Liver Metastasis. Cancers 15:13, pages 3513.
Crossref
Fnu Amisha, Paras Malik, Prachi Saluja, Nitesh Gautam, Tanvi Harishbhai Patel, Arya Mariam Roy, Sunny R. K. Singh & Sindhu Janarthanam Malapati. (2023) A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers. Onco 3:2, pages 96-124.
Crossref
Hideaki Bando, Atsushi Ohtsu & Takayuki Yoshino. (2023) Therapeutic landscape and future direction of metastatic colorectal cancer. Nature Reviews Gastroenterology & Hepatology 20:5, pages 306-322.
Crossref
Dongdong Zhan, Nairen Zheng, Beibei Zhao, Fang Cheng, Qi Tang, Xiangqian Liu, Juanfei Wang, Yushen Wang, Haibo Liu, Xinliang Li, Juming Su, Xuejun Zhong, Qing Bu, Yating Cheng, Yi Wang & Jun Qin. (2023) Expanding individualized therapeutic options via genoproteomics. Cancer Letters 560, pages 216123.
Crossref
Eléonore Spitzer, Pascale Cervera, Thierry André & Romain Cohen. (2023) Cibler HER2 dans le cancer colorectal. Bulletin du Cancer 110:4, pages 402-411.
Crossref
Samar Al Bitar, Marwan El-Sabban, Samer Doughan & Wassim Abou-Kheir. (2023) Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World Journal of Gastroenterology 29:9, pages 1395-1426.
Crossref
Yuan-Ling Tang, Dan-Dan Li, Jia-Yu Duan, Lei-Ming Sheng & Xin Wang. (2023) Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World Journal of Gastroenterology 29:6, pages 926-948.
Crossref
Shruti GohelViraj Lavingia. (2023) HER2 ‘neu’ promise for mCRC. International Journal of Molecular and Immuno Oncology 8, pages 3-8.
Crossref
Ting Xu, Xicheng Wang, Ying Xin, Zhenghang Wang, Jifang Gong, Xiaotian Zhang, Yanyan Li, Congcong Ji, Yu Sun, Feilong Zhao, Depei Huang, Yuezong Bai, Jian Li & Lin Shen. (2022) Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II single-arm study and exploratory biomarker analysis. Cancer Research and Treatment.
Crossref
Giulia Dazio, Samantha Epistolio, Milo Frattini & Piercarlo Saletti. (2022) Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. Journal of Clinical Medicine 11:24, pages 7523.
Crossref
Lu Yang, Arup Bhattacharya, Yun Li, Sandra Sexton, Xiang Ling, Fengzhi Li & Yuesheng Zhang. (2022) Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Liu Yang, Wenfei Li, Zhihao Lu, Ming Lu, Jun Zhou, Zhi Peng, Xiaotian Zhang, Xicheng Wang, Lin Shen & Jian Li. (2022) Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment. BMC Cancer 22:1.
Crossref
Ranju Gupta, Funda Meric-Bernstam, Michael Rothe, Elizabeth Garrett-Mayer, Pam K. Mangat, Stacy D'Andre, Eugene R. Ahn, Raegan O'Lone, Susan Halabi, Gina N. Grantham & Richard L. Schilsky. (2022) Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study . JCO Precision Oncology:6.
Crossref
Mariia Ivanova, Konstantinos Venetis, Elena Guerini-Rocco, Luca Bottiglieri, Mauro Giuseppe Mastropasqua, Ornella Garrone, Nicola Fusco & Michele Ghidini. (2022) HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes. Life 12:9, pages 1403.
Crossref
Canan Karan, Elaine Tan, Humaira Sarfraz, Todd C. Knepper, Christine M. Walko, Seth Felder, Richard Kim & Ibrahim Halil Sahin. (2022) Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues. JCO Oncology Practice 18:8, pages 545-554.
Crossref
Javier Torres-Jiménez, Jorge Esteban-Villarrubia & Reyes Ferreiro-Monteagudo. (2022) Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. Cancers 14:15, pages 3718.
Crossref
Selma Ahcene Djaballah, Francesca Daniel, Anna Milani, Gianmarco Ricagno & Sara Lonardi. (2022) HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. American Society of Clinical Oncology Educational Book:42, pages 219-232.
Crossref
Rita Saúde-Conde, Gertjan Rasschaert, Giacomo Bregni, Alain Hendlisz & Francesco Sclafani. (2022) Mind the target: human epidermal growth factor receptor 2 in colorectal cancer. Current Opinion in Oncology 34:4, pages 382-388.
Crossref
Peng Ye, Yiran Wang, Ruiqi Li, Wanlu Chen, Lu Wan & Peiling Cai. (2022) The HER family as therapeutic targets in colorectal cancer. Critical Reviews in Oncology/Hematology 174, pages 103681.
Crossref
Lakshmi Sai Vijay Achalla, Raju K Shinde, Sangita Jogdand & Sahitya Vodithala. (2022) Review of the Role of HER2/neu in Colorectal Carcinomas. Cureus.
Crossref
John H. Strickler, Takayuki Yoshino, Rondell P. Graham, Salvatore Siena & Tanios Bekaii-Saab. (2022) Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. JAMA Oncology 8:5, pages 760.
Crossref
Ali Abdulnabi Suwaidan, David K. Lau & Ian Chau. (2022) HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews 105, pages 102363.
Crossref
Juan Ruiz-Bañobre, Elena Brozos-Vázquez, Francisca Vázquez-Rivera, Yolanda Vidal-Ínsua, Rafael López-López & Sonia Candamio-Folgar. 2022. Foundations of Colorectal Cancer. Foundations of Colorectal Cancer 357 364 .
Sara Cherri, Michela Libertini & Alberto Zaniboni. (2021) New drugs for the treatment of metastatic colorectal cancer. World Journal of Gastrointestinal Oncology 13:11, pages 1551-1560.
Crossref
Federica Di Nicolantonio, Pietro Paolo Vitiello, Silvia Marsoni, Salvatore Siena, Josep Tabernero, Livio Trusolino, Rene Bernards & Alberto Bardelli. (2021) Precision oncology in metastatic colorectal cancer — from biology to medicine. Nature Reviews Clinical Oncology 18:8, pages 506-525.
Crossref
Chiara Guarini, Teresa Grassi, Gaetano Pezzicoli & Camillo Porta. (2021) Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. International Journal of Molecular Sciences 22:13, pages 6813.
Crossref
Juan Ruiz-Bañobre & Ajay Goel. 2021. Novel Approaches to Colorectal Cancer. Novel Approaches to Colorectal Cancer 231 304 .
Csongor G. Lengyel, Baker Habeeb, Shah Z. Khan, Khalid El Bairi, Sara C. Altuna, Sadaqat Hussain, Syed Ayub Mazher, Dario Trapani & Angelica Petrillo. (2020) Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. Gastrointestinal Disorders 3:1, pages 1-22.
Crossref
Jonathan A. Nowak. (2020) HER2 in Colorectal Carcinoma. Surgical Pathology Clinics 13:3, pages 485-502.
Crossref
Astrid De Cuyper, Marc Van Den Eynde & Jean-Pascal Machiels. (2020) HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. Clinical Colorectal Cancer 19:2, pages 65-72.
Crossref
G. Wang, Y. He, Y. Sun, W. Wang, X. Qian, X. Yu & Y. Pan. (2019) Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer. Clinical and Translational Oncology 22:6, pages 813-822.
Crossref
Yuan-Hong Xie, Ying-Xuan Chen & Jing-Yuan Fang. (2020) Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy 5:1.
Crossref
Anna Maria Rachiglio, Alessandra Sacco, Laura Forgione, Claudia Esposito, Nicoletta Chicchinelli & Nicola Normanno. (2020) Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. Exploration of Targeted Anti-tumor Therapy 1:1, pages 53-70.
Crossref
Do-Youn Oh & Yung-Jue Bang. (2019) HER2-targeted therapies — a role beyond breast cancer. Nature Reviews Clinical Oncology 17:1, pages 33-48.
Crossref
Anita Sveen, Scott Kopetz & Ragnhild A. Lothe. (2019) Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical Oncology 17:1, pages 11-32.
Crossref
A. A. Kachmazov, L. V. Bolotina, A. L. Kornietskaya, T. V. Ustinova, V. A. Tolstov & A. A. Fedenko. (2019) Possibilities of therapeutic use of HER2-inhibitorsin metastatic colorectal cancer: a case report. Medical Council:19, pages 126-131.
Crossref
Basile Tessier-Cloutier, Ellen Cai & David F. Schaeffer. (2019) Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. Diagnostic Pathology 14:1.
Crossref
Xin-Yu Wang, Zhi-Xue Zheng, Yu Sun, Yan-Hua Bai, Yun-Fei Shi, Li-Xin Zhou, Yun-Feng Yao, Ai-Wen Wu & Deng-Feng Cao. (2019) Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas . World Journal of Gastrointestinal Oncology 11:4, pages 335-347.
Crossref
Rutika Mehta. (2018) The Role of HER2 Testing in Advanced Colorectal Cancer. Current Colorectal Cancer Reports 14:6, pages 184-191.
Crossref
Megan Greally, Ciara M. Kelly & Andrea Cercek. (2018) HER2: An emerging target in colorectal cancer. Current Problems in Cancer 42:6, pages 560-571.
Crossref
Ozkan Kanat, Hulya Ertas & Burcu Caner. (2018) Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. World Journal of Clinical Cases 6:11, pages 418-425.
Crossref
Guixia Pan, Danni Li, Xiao Li, Ye Peng, Tao Wang & Changjing Zuo. (2018) SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin. Biochemical and Biophysical Research Communications 504:4, pages 765-770.
Crossref
S. Siena, A. Sartore-Bianchi, S. Marsoni, H.I. Hurwitz, S.J. McCall, F. Penault-Llorca, S. Srock, A. Bardelli & L. Trusolino. (2018) Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology 29:5, pages 1108-1119.
Crossref
Erika Martinelli, Teresa Troiani, Vincenzo Sforza, Giulia Martini, Claudia Cardone, PietroPaolo Vitiello, Davide Ciardiello, AnnaMaria Rachiglio, Nicola Normanno, Andrea Sartore-Bianchi, Silvia Marsoni, Alberto Bardelli, Salvatore Siena & Fortunato Ciardiello. (2018) Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open 3:1, pages e000299.
Crossref
L. V. K. S. Bhaskar & L. Saikrishna. 2018. Role of Tyrosine Kinases in Gastrointestinal Malignancies. Role of Tyrosine Kinases in Gastrointestinal Malignancies 191 224 .
Jason Paik, Cindy Kin & George A. Fisher. 2018. Surgical Techniques in Rectal Cancer. Surgical Techniques in Rectal Cancer 111 124 .
Naoki Takegawa & Kimio Yonesaka. (2017) HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. Clinical Colorectal Cancer 16:4, pages 247-251.
Crossref
Nesa Sayadnejad, Alireza Firouzjahi, Shahryar Shafaee, Hannaneh Golshahi, Zahra Sokouti, Hemmat Gholinia & Mohammad Ranaee. (2017) Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors. International Journal of Cancer Management 10:5.
Crossref
Chloe E. AtreyaRona YaegerEdward Chu. (2017) Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. American Society of Clinical Oncology Educational Book:37, pages 246-256.
Crossref
Hye Seung Lee, Woo Ho Kim, Yoonjin Kwak, Jiwon Koh, Jeong Mo Bae, Kyoung-Mee Kim, Mee Soo Chang, Hye Seung Han, Joon Mee Kim, Hwal Woong Kim, Hee Kyung Chang, Young Hee Choi, Ji Y. Park, Mi Jin Gu, Min Jin Lhee, Jung Yeon Kim, Hee Sung Kim & Mee-Yon Cho. (2017) Molecular Testing for Gastrointestinal Cancer. Journal of Pathology and Translational Medicine 51:2, pages 103-121.
Crossref
Rodrigo Dienstmann, Louis Vermeulen, Justin Guinney, Scott Kopetz, Sabine Tejpar & Josep Tabernero. (2017) Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer 17:2, pages 79-92.
Crossref
Asma Shabbir, Talat Mirza, Abdullah Bin Khalid, Muhammad Asif Qureshi & Sadaf Ahmed Asim. (2016) Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country. BMC Cancer 16:1.
Crossref
Anke Reinacher-Schick. (2016) Neues Target beim fortgeschrittenen kolorektalen KarzinomNew target for advanced colorectal carcinoma. Der Onkologe 22:12, pages 994-995.
Crossref
Valentina Fanotto, Elena Ongaro, Karim Rihawi, Antonio Avallone, Nicola Silvestris, Lorenzo Fornaro, Enrico Vasile, Lorenzo Antonuzzo, Francesco Leone, Gerardo Rosati, Francesco Giuliani, Roberto Bordonaro, Mario Scartozzi, Giovanna De Maglio, Francesca V. Negri, Gianpiero Fasola & Giuseppe Aprile. (2016) HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget 7:42, pages 69060-69074.
Crossref
A. Sartore-Bianchi, F. Loupakis, G. Argilés & G.W. Prager. (2016) Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology 27:8, pages 1456-1466.
Crossref
Hans-Joachim Schmoll. (2016) Targeting HER2: precision oncology for colorectal cancer. The Lancet Oncology 17:6, pages 685-686.
Crossref
Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino, Sara Lonardi, Francesca Bergamo, Vittorina Zagonel, Francesco Leone, Ilaria Depetris, Erika Martinelli, Teresa Troiani, Fortunato Ciardiello, Patrizia Racca, Andrea Bertotti, Giulia Siravegna, Valter Torri, Alessio Amatu, Silvia Ghezzi, Giovanna Marrapese, Laura Palmeri, Emanuele Valtorta, Andrea Cassingena, Calogero Lauricella, Angelo Vanzulli, Daniele Regge, Silvio Veronese, Paolo M Comoglio, Alberto Bardelli, Silvia Marsoni & Salvatore Siena. (2016) Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. The Lancet Oncology 17:6, pages 738-746.
Crossref
Garrett S. Barry, Maggie C. Cheang, Hector Li Chang & Hagen F. Kennecke. (2016) Genomic markers of panitumumab resistance including ERBB2/HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). Oncotarget 7:14, pages 18953-18964.
Crossref
Florian Eisner, Martin Pichler, Steffen Goletz, Herbert Stoeger & Hellmut Samonigg. (2015) A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options. Journal of Clinical Pathology 68:12, pages 1044.1-1046.
Crossref
Michael S. Lee & Scott Kopetz. (2015) Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. Clinical Colorectal Cancer 14:4, pages 203-218.
Crossref
Alexis D. Leal, Joleen Hubbard, Daniel Sargent & Axel Grothey. (2015) New Adjuvant Trial Designs in Colon Cancer. Current Colorectal Cancer Reports 11:6, pages 326-334.
Crossref
Emanuele Valtorta, Cosimo Martino, Andrea Sartore-Bianchi, Frédérique Penaullt-Llorca, Giuseppe Viale, Mauro Risio, Massimo Rugge, Walter Grigioni, Katia Bencardino, Sara Lonardi, Vittorina Zagonel, Francesco Leone, Johannes Noe, Fortunato Ciardiello, Carmine Pinto, Roberto Labianca, Stefania Mosconi, Claudio Graiff, Giuseppe Aprile, Barbara Frau, Carlo Garufi, Fotios Loupakis, Patrizia Racca, Giuseppe Tonini, Calogero Lauricella, Silvio Veronese, Mauro Truini, Salvatore Siena, Silvia Marsoni & Marcello Gambacorta. (2015) Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Modern Pathology 28:11, pages 1481-1491.
Crossref
Phillip R. Stahl, Jessica Schnellert, Christina Koop, Ronald Simon, Andreas Marx, Jakob R. Izbicki, Guido Sauter & Alexander Quaas. (2015) Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. Pathology & Oncology Research 21:4, pages 1183-1189.
Crossref
Andrea Bertotti & Francesco Sassi. (2015) Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clinical Cancer Research 21:15, pages 3377-3383.
Crossref
Norhayati Omar, Benedict Yan & Manuel Salto-Tellez. (2015) HER2: An emerging biomarker in non-breast and non-gastric cancers. Pathogenesis 2:3, pages 1-9.
Crossref
Mark Sausen, Jillian Phallen, Vilmos Adleff, Siân Jones, Rebecca J. Leary, Michael T. Barrett, Valsamo Anagnostou, Sonya Parpart-Li, Derek Murphy, Qing Kay Li, Carolyn A. Hruban, Rob Scharpf, James R. White, Peter J. O’Dwyer, Peter J. Allen, James R. Eshleman, Craig B. Thompson, David S. Klimstra, David C. Linehan, Anirban Maitra, Ralph H. Hruban, Luis A. DiazJr.Jr., Daniel D. Von Hoff, Julia S. Johansen, Jeffrey A. Drebin & Victor E. Velculescu. (2015) Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications 6:1.
Crossref
Umut Disel, Alexis Germain, Bahar Yilmazel, Huseyin Abali, Filiz Aka Bolat, Roman Yelensky, Julia A. Elvin, Doron Lipson, Juliann Chmielecki, Kai Wang, Philip J. Stephens, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali & Thomas J. George Jr.. (2015) Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. Oncoscience 2:6, pages 581-584.
Crossref
Yuhei Kinehara, Toshiyuki Minami, Takashi Kijima, Shigenori Hoshino, Osamu Morimura, Tomoyuki Otsuka, Yoshitomo Hayama, Kiyoharu Fukushima, Yoshiko Takeuchi, Masayoshi Higashiguchi, Kotaro Miyake, Haruhiko Hirata, Izumi Nagatomo, Koji Inoue, Yoshito Takeda, Hiroshi Kida & Atsushi Kumanogoh. (2015) Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer. Lung Cancer 87:3, pages 321-325.
Crossref
JINHUA TU, YINGHAO YU, WEI LIU & SHUNPING CHEN. (2015) Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Experimental and Therapeutic Medicine 9:1, pages 17-24.
Crossref
Edward L Nelson. (2014) HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations. Clinical Investigation 4:9, pages 791-823.
Crossref
Siao-Syun Guan, Jungshan Chang, Chun-Chia Cheng, Tsai-Yueh Luo, Ai-Sheng Ho, Chia-Chi Wang, Cheng-Tien Wu & Shing-Hwa Liu. (2014) Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo . Oncotarget 5:13, pages 4868-4880.
Crossref
Min Yan, Barbara A. Parker, Richard Schwab & Razelle Kurzrock. (2014) HER2 aberrations in cancer: Implications for therapy. Cancer Treatment Reviews 40:6, pages 770-780.
Crossref
Teresa Troiani, Filippo Venturini, Stefania Napolitano, Giulia Martini, Valentina Gambardella, Fortunato Ciardiello & Erika Martinelli. (2014) Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer. Colorectal Cancer 3:3, pages 299-308.
Crossref
Won‐Suk Lee, Yeon Ho Park, Jung Nam Lee, Jeong‐Heum Baek, Tae‐Hoon Lee & Seung Yeon Ha. (2014) Comparison of HER 2 expression between primary colorectal cancer and their corresponding metastases . Cancer Medicine 3:3, pages 674-680.
Crossref
An Na Seo, Yoonjin Kwak, Duck-Woo Kim, Sung-Bum Kang, Gheeyoung Choe, Woo Ho Kim & Hye Seung Lee. (2014) HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression. PLoS ONE 9:5, pages e98528.
Crossref
Geraldine Perkins, Camilla Pilati, Helene Blons & Pierre Laurent-Puig. (2014) Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. Pharmacogenomics 15:7, pages 1043-1052.
Crossref
Eike Burandt, Melanie Schreiber, Alexander Stein, Sarah Minner, Till S. Clauditz, Carsten Bokemeyer, Fritz Jänicke, Margit Fisch, Jakob R. Izbicki, Rainald Knecht, Guido Sauter & Phillip R. Stahl. (2014) Continuous tissue microarray based identification of cancers with homogeneous target expression for successful targeted therapy in clinical routine practice. Genes, Chromosomes and Cancer 53:3, pages 228-239.
Crossref
Douglas A. Rubinson, Howard S. Hochster, David P. Ryan, Brian M. Wolpin, Nadine Jackson McCleary, Thomas A. Abrams, Jennifer A. Chan, Syma Iqbal, Heinz J. Lenz, Dean Lim, Jeffrey Rose, Tanios Bekaii-Saab, Helen X. Chen, Charles S. Fuchs & Kimmie Ng. (2013) Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. Investigational New Drugs 32:1, pages 113-122.
Crossref
Satoshi IKEDA, Chigusa NAGATA & Keiko SUZUKI. (2014) Detection of HER-2 Protein and DNA Amplification in Breast, Stomach and Colon Cancers. JOURNAL OF THE JAPANESE ASSOCIATION OF RURAL MEDICINE 63:2, pages 99-104.
Crossref
F. Sclafani, A. Roy, D. Cunningham, A. Wotherspoon, C. Peckitt, D. Gonzalez de Castro, J. Tabernero, B. Glimelius, A. Cervantes, Z. Eltahir, J. Oates & I. Chau. (2013) HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Annals of Oncology 24:12, pages 3123-3128.
Crossref
Sing Yu Moorcraft, Elizabeth C. Smyth & David Cunningham. (2013) The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therapeutic Advances in Gastroenterology 6:5, pages 381-395.
Crossref
Sang-Woo Lim, Hye-Ran Kim, Hwan-Young Kim, Jung-Wook Huh, Young-Jin Kim, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang, Hyeong-Rok Kim & Myung-Geun Shin. (2013) Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor. Cellular Oncology 36:4, pages 311-321.
Crossref
Giuseppe Aprile, Giovanna De Maglio, Jessica Menis, Mariaelena Casagrande, Francesco Tuniz, Edith Pisa, Caterina Fontanella, Miran Skrap, Alberto Beltrami, Gianpiero Fasola & Stefano Pizzolitto. (2013) HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series. International Journal of Molecular Sciences 14:2, pages 2370-2387.
Crossref
Erik J BlokPeter JK KuppenJeroen EM van LeeuwenCornelis FM Sier. (2013) Cytoplasmic Overexpression of HER2: A Key Factor in Colorectal Cancer. Clinical Medicine Insights: Oncology 7, pages CMO.S10811.
Crossref
Halit Karaca, Kemal Deniz, Veli Berk, Mevlude Inanc & Metin Ozkan. (2012) Association of Human Epidermal Growth Factor Receptor-2 Expression and Clinicopathological Findings in Patients with Colorectal Cancer. Asian Pacific Journal of Cancer Prevention 13:12, pages 6221-6225.
Crossref
Luigi Aurisicchio, Emanuele Marra, Giuseppe Roscilli, Rita Mancini & Gennaro Ciliberto. (2012) The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget 3:8, pages 744-758.
Crossref
Leopoldo Luistro. (2012) Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab. International Journal of Oncology.
Crossref
Andreas H. Marx, Eike C. Burandt, Matthias Choschzick, Ronald Simon, Emre Yekebas, Jussuf T. Kaifi, Martina Mirlacher, Djordje Atanackovic, Carsten Bokemeyer, Walter Fiedler, Luigi Terracciano, Guido Sauter & Jakob R. Izbicki. (2010) Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Human Pathology 41:11, pages 1577-1585.
Crossref
Rahul A. Sheth & Umar Mahmood. (2010) Optical molecular imaging and its emerging role in colorectal cancer. American Journal of Physiology-Gastrointestinal and Liver Physiology 299:4, pages G807-G820.
Crossref
István Peták, Richárd Schwab, László Őrfi, László Kopper & György Kéri. (2010) Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews Drug Discovery 9:7, pages 523-535.
Crossref
Dara O Kavanagh, Gillian Chambers, Liam O' Grady, Kevin M Barry, Ronan P Waldron, Fadel Bennani, Paul W Eustace & Iqdam Tobbia. (2009) Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?. BMC Cancer 9:1.
Crossref
Michael Pohl, I. Stricker, A. Schoeneck, K. Schulmann, S. Klein-Scory, I. Schwarte-Waldhoff, M. Hasmann, A. Tannapfel, W. Schmiegel & A. Reinacher-Schick. (2009) Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo. Journal of Cancer Research and Clinical Oncology 135:10, pages 1377-1386.
Crossref
William H. Fiske, David Threadgill & Robert J. Coffey. (2009) ERBBs in the gastrointestinal tract: Recent progress and new perspectives. Experimental Cell Research 315:4, pages 583-601.
Crossref
G Sithanandam & L M Anderson. (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Therapy 15:7, pages 413-448.
Crossref
Sher-Ping Leung, Obi L. Griffith, Hamid Masoudi, Allen Gown, Steven Jones, Terry Phang & Sam M. Wiseman. (2008) Clinical utility of type 1 growth factor receptor expression in colon cancer. The American Journal of Surgery 195:5, pages 604-610.
Crossref
Kathleen Seitz & Ghui Zhou. (2013) Pharmacokinetic Drug‐Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check. The Journal of Clinical Pharmacology 47:9, pages 1104-1118.
Crossref
Elizabeth Half, Yunjie Sun & Frank A. Sinicrope. (2007) Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. Cancer Letters 251:2, pages 237-246.
Crossref
Howard Safran, Thomas DiPetrillo, Paul Akerman, Thomas Ng, Devon Evans, Margaret Steinhoff, David Benton, John Purviance, Lisa Goldstein, Umadevi Tantravahi & Teresa Kennedy. (2007) Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. International Journal of Radiation Oncology*Biology*Physics 67:2, pages 405-409.
Crossref
B Schuell, T Gruenberger, W Scheithauer, Ch Zielinski & F Wrba. (2006) HER 2/neu protein expression in colorectal cancer. BMC Cancer 6:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.